|
|
|
|
GMMMG Consultations |
|
|
On this page you will find proposed changes that are currently going through the GMMMG approval process. This will include consultations on proposed RAG status, updated Formulary Chapters, Pathways or other GMMMG Guidance. You will be able to comment on current proposals via the links in the table below. |
|
|
Title |
Information |
Feedback |
End date |
|
|
27 |
The GM asthma working group have updated the GM asthma management plan following publication of NICE’s asthma guideline NG80. The main updates to the GM asthma management plan are as follows:
Please submit any comments using the feedback form. This consultation will close at 5pm on Friday 29th June 2018. Industry are invited to comment on factual inaccuracy only. |
5pm Friday |
||
|
26 |
Under the direction of the GM Clinical Standards Board, the Pathways and Guidelines Development Subgroup are working to develop a GM resource pack for opioid prescribing for chronic pain. Wigan Borough CCG have produced a resource pack which we are looking to implement across GM. This document is now open for GM-wide consultation in line with the GMMMG approval process. Please submit any comments using the feedback form. This consultation will close at 5pm on Friday 15th June 2018. Industry are invited to comment on factual inaccuracy only. |
5pm Friday |
||
|
|
||||
|
25 |
PCSK9 inhibitor Blueteq forms |
We are asking for comments on the PCSK9 inhibitor Blueteq forms which are currently live on the system. The questions appear to be in line with NICE and GMMMG recommendation but are wordy. However the clinician response are mainly tick boxes so should be quick to complete. Please feedback any changes you think may be beneficial to the Greater Manchester services using these PCSK9 inhibitor forms. A summary of the questions on the initiation form are below Q1 is asking for standard treatment prior to biosimilar (tick for why discontinued and tick which drugs tried) Q2 is asking for LDLc scores; it could be removed but the LDL-c may be used by trusts to monitor the change in LDLc from initiation to continuation Q3 is a tick for which category the patient fits into (matching table 1 in NICE)Q4 could go if we assume the patient is told they may have their treatment stopped Q5 is info regarding when a continuation is expected. |
5pm Friday |
|
|
24 |
FMESG - proposed actions for consultation |
The following actions were proposed at the March 2018 FMESG meeting, approved in principle by GMMMG in April, and are now open for GM wide consultation. Comments are invited up until 5pm Tuesday 15th May 2018 |
Feedback Form |
5pm Tuesday |
|
23 |
GM Model Framework for dermatology services |
Under direction of the GM Directors of Commissioning the GM Dermatology Group are developing the GM Model Framework for dermatology services. The group has produced a series of educational tools which will help to improve confidence of managing skin in primary care and upskill clinicians in primary care at the same time. Included in the educational pack is: |
5pm Wednesday |
|
|
A GM pathway of care from primary care to tertiary care Refreshed skin chapter |
|
|
||
|
A number of these are now opened (see links above) for GM wide consultation in line with the GMMMG approval process. Please submit any comments using the appropriate feedback form links above, this consultation will close at 5pm Wednesday 30th May 2018. Industry are invited to comment on factual inaccuracy only. |
||||
|
22 |
The Greater Manchester DNP and grey lists have been revised to reflect recent NHS England guidance. Please note that the list contains items previously considered by GMMMG and not included in the NHS England list. Changes to these items are purely editorial, in order to harmonise wording throughout. The list also contains three new items to be considered for inclusion. The revised list is now open for GM-wide consultation for 6 weeks. Industry are invited to comment on factual inaccuracies only. Following consultation the list will be taken forward to AGG for policy development. Comments are invited up until 5pm on Tuesday 22nd May 2018 and should be submitted here. |
5pm Tuesday |
||
|
21 |
Ciclosporin for childhood nephrotic syndrome |
On behalf of the GMMMG Pathways and Guidelines Development Subgroup, a Greater Manchester wide Shared Care Protocol for ciclosporin for childhood nephrotic syndrome [Link removed - consultation closed] is in development. We now seek the comments of all GM NHS healthcare professionals on this draft. This consultation period is open until 5pm on 18th May 2018. |
Feedback Form |
5pm Friday |
|
20 |
Sulfasalazine for inflammatory bowel disease |
On behalf of the GMMMG Pathways and Guidelines Development Subgroup, a Greater Manchester wide Shared Care Protocol for sulfasalazine for inflammatory bowel disease [Link removed - consultation closed] is in development. We now seek the comments of all GM NHS healthcare professionals on this draft. This consultation period is open until 5pm on 18th May 2018. |
Feedback Form |
5pm Friday |
|
19 |
Domperidone for paediatric gastro-oesophageal reflux disease |
On behalf of the GMMMG Pathways and Guidelines Development Subgroup, a Greater Manchester wide Shared Care Protocol for domperidone for paediatric gastro-oesophageal reflux disease [Link removed - consultation closed] is in development. We now seek the comments of all GM NHS healthcare professionals on this draft. This consultation period is open until 5pm on 18th May 2018. |
Feedback Form |
5pm Friday |
|
18 |
Disulfiram for alcohol dependence |
On behalf of the GMMMG Pathways and Guidelines Development Subgroup, a Greater Manchester wide Shared Care Protocol for disulfiram for alcohol dependence [Link removed - consultation closed] is in development. We now seek the comments of all GM NHS healthcare professionals on this draft. This consultation period is open until 5pm on 18th May 2018. |
Feedback Form |
5pm Friday |
<< Back
